性激素预处理在体外受精胚-胎移植超促排卵拮抗剂方案中的应用

摘要
图/表
参考文献
相关文章 (10)

全文: PDF (638 KB) HTML (29 KB)
输出: BibTeX | EndNote (RIS)

摘要促性腺激素拮抗剂方案由于不需要对垂体进行降调节,促排卵时间短,在体外受精-胚胎移植技术临床上的应用越来越多,女性卵巢储备功能及对超促排卵药物的反应不同,性激素预处理在不同的卵巢反应人群的侧重点不同。高反应人群和正常反应人群通过拮抗剂方案能够很有效地降低卵巢过度刺激综合征发生风险,性激素预处理对于高反应人群是基于改善异常的性激素指标,提高卵子及胚胎的质量;正常反应人群和低反应人群性激素预处理是基于卵泡发育的均一性、增加获得卵子和胚胎的数量和质量;另外就是临床工作时间的安排等,性激素预处理应用的必要性和方法在临床上不统一。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	任普佳
	陈秀娟

关键词 ：性激素, 预处理, 拮抗剂方案

收稿日期: 2021-12-20

ZTFLH:

R71

基金资助:内蒙古自治区科技计划项目(2021GG0389)

通讯作者: 陈秀娟( 90098687@sina.com)

引用本文:

任普佳, 陈秀娟. 性激素预处理在体外受精胚-胎移植超促排卵拮抗剂方案中的应用[J]. 中国生育健康杂志, 2023, 34(3): 290-293.

链接本文:

http://cjrh.bjmu.edu.cn/CN/ 或 http://cjrh.bjmu.edu.cn/CN/Y2023/V34/I3/290

1 胡琳莉,陈彩虹.控制性卵巢刺激方案的新理念.实用妇产科杂志,2020,36:241-242.
2 陈志燕,金力.多囊卵巢综合征的高雄激素血症对生育的影响.中华妇产科杂志,2019,54:425-428.
3 林秀峰,伍畅,郑湘琼,等.游离睾酮指数对多囊卵巢综合征不孕患者IVF-ET治疗妊娠结局的预测价值.生殖医学杂志,2016,25:135-138.
4 Pan JX,Liu Y,Ke ZH,et al.Successive and cyclic oral contraceptive pill pretreatment improves IVF/ICSI outcomes of PCOS patients and ameliorates hyperandrogenism and antral follicle excess.Gynecol Endocrinol,2015,31:332-336.
5 Bindu N.Chimote M.Sc.,M.Phil,Ph.D.Is the ‘oestro-androgenic’ hormone dehydro-epiandrosterone sulphate (DHEAS) the intracrine regulator of implantation and early pregnancy?a prospective study in women undergoing IVF.Fertil Steril,2019,112,188.
6 Fukuda M,Fukuda K,Yding Andersen C,Byskov AG.Does anovulation induced by oral contraceptives favor pregnancy during the following two menstrual cycles? Fertil Steril 2000,73:742747.
7 Ozmen B,Sükür YE,Seval MM,et al.Dual suppression with oral contraceptive pills in GnRH antagonist cycles for patients with polycystic ovary syndrome undergoing intracytoplasmic sperm injection.Eur J Obstet Gynecol Reprod Biol,2014,183:137-140.
8 Pinkas H,Sapir O,Avrech OM,et al.The effect of oral contraceptive pill for cycle scheduling prior to GnRHantagonist protocol on IVF cycle parameters and pregnancy outcome.J Assist Reprod Genet 2008,25:2933.
9 Wei D,Shi Y,Li J,et al.Effect of pretreatment with oral contraceptives and progestins on IVF outcomes in women with polycystic ovary syndrome.Hum Reprod,2017,32:354-361.
10 Montoya-Botero P,Martinez F,Rodríguez-Purata J,et al.Erratum.The effect of type of oral contraceptive pill and duration of use on fresh and cumulative live birth rates in IVF/ICSI cycles.Hum Reprod,2021,36:1159-1161.
11 ESHRE Guideline Group on Ovarian Stimulation,Bosch E,Broer S,et al.Erratum:ESHRE guideline:ovarian stimulation for IVF/ICSI.Hum Reprod Open,2020,2020:hoaa067.
12 李卓,李蓉.女性高雄激素对妊娠和子代影响的研究进展.中华生殖与避孕杂志,2020,40:837-841.
13 Li Y,Ruan X,Wang H,et al.Comparing the risk of adverse pregnancy outcomes of Chinese patients with polycystic ovary syndrome with and without antiandrogenic pretreatment.Fertil Steril.2018,109:720-727.
14 易思思,梁新红,丘映.GnRH拮抗剂方案中雌激素预处理与正常反应患者临床结局的Meta分析.生殖医学杂志,2017,26:345-350.
15 Pereira N,Petrini AC,Zhou ZN,et al.Pretreatment of normal responders in fresh in vitro fertilization cycles:A comparison of transdermal estradiol and oral contraceptive pills.Clin Exp Reprod Med,2016,43:228-232.
16 Cédrin-Durnerin I,Guivarćh-Levêque A,Hugues JN.Pretreatment with estrogen does not affect IVF-ICSI cycle outcome compared with no pretreatment in GnRH antagonist protocol:a prospective randomized trial.Fertil Steril,2012,97:1359-1364.e1.
17 Sefrioui O,Madkour A,Kaarouch I,et al.Luteal estradiol pretreatment of poor and normal responders during GnRH antagonist protocol.Gynecol Endocrinol,2019,35:1067-1071.
18 Shahrokh Tehrani Nejad E,Bakhtiari Ghaleh F,Eslami B,et al.Comparison of pre-treatment with OCPs or estradiol valerate vs.no pre-treatment prior to GnRH antagonist used for IVF cycles:An RCT.Int J Reprod Biomed,2018,16:535-540.
19 Andersen AN,Witjes H,Gordon K,et al.Predictive factors of ovarian response and clinical outcome after IVF/ICSI following a rFSH/GnRH antagonist protocol with or without oral contraceptive pre-treatment.Hum Reprod,2011,26:3413-3423.
20 Li J,Sun Y,Mo S,et al.Effects of oral contraceptive for different responder women before GnRH antagonists:a systematic review and meta-analysis.Gynecol Endocrinol,2021,37:977-986.
21 Chimote BN,Chimote NM.Fertility interventions 'add-ons' in clinical ARTpractice:Ethical,Moral and Commercial Considerations.J Assist Reprod Genet,2021,38:2579-2580.
22 Qin JC,Fan L,Qin AP.The effect of dehydroepiandrosterone (DHEA) supplementation on women with diminished ovarian reserve (DOR) in IVF cycle:Evidence from a meta-analysis.J Gynecol Obstet Hum Reprod,2017,46:1-7.
23 Keane KN,Hinchliffe PM,Rowlands PK,et al.DHEA supplementation confers no additional benefit to that of growth hormone on pregnancy and live birth rates in IVF patients categorized as poor prognosis.Front Endocrinol (Lausanne),2018,9:14.
24 Sciard,C.,Berthiller,J.,Brosse,A.et al.Preliminary results of DHEA in poor responders in IVF.Open J Obstet Gynecol,2016,6:396-403.
25 Zhang D,Gao J,Liu X,et al.Effect of three androgen indexes (FAI,FT,and TT) on clinical,biochemical,and fertility outcomes in women with polycystic ovary syndrome.Reprod Sci,2021,28:775-784.
26 Vlahos N,Papalouka M,Triantafyllidou O,et al.Dehydroepiandrosterone administration before IVF in poor responders:a prospective cohort study.Reprod Biomed Online,2015,30:191-196.
27 Qin JC,Fan L,Qin AP.The effect of dehydroepiandrosterone (DHEA) supplementation on women with diminished ovarian reserve (DOR) in IVF cycle:Evidence from a meta-analysis.J Gynecol Obstet Hum Reprod,2017,46:1-7.
28 Triantafyllidou O,Sigalos G,Vlahos N.Dehydroepiandrosterone (DHEA) supplementation and IVF outcome in poor responders.Hum Fertil (Camb),2017,20:80-87.
29 Kim CH,Ahn JW,Moon JW,et al.Ovarian features after 2 weeks,3 weeks and 4 weeks transdermal testosterone gel treatment and their associated effect on IVF outcomes in poor responders.Dev Reprod,2014,18:145-152.
30 Luo S,Li S,Li X,et al.Effect of pretreatment with transdermal testosterone on poor ovarian responders undergoing IVF/ICSI:A meta-analysis.Exp Thr Med,2014,8:187-194.
31 Nassar J,Tadros T,Adda-Herzog E,et al.Steroid hormone pretreatments in assisted reproductive technology.Fertil Steril,2016,106:1608-1614.
32 王彩霞,刘芸,黄吴键,等.雌激素预处理在不同卵巢反应人群使用拮抗剂方案中的应用研究.中华生殖与避孕杂志,2020,40:708-715.
33 Lee H,Choi HJ,Yang KM,et al.Efficacy of luteal estrogen administration and an early follicular Gonadotropin-releasing hormone antagonist priming protocol in poor responders undergoing in vitro fertilization.Obstet Gynecol Sci,2018,61:102-110.
34 Shastri SM,Barbieri E,Kligman I,et al.Stimulation of the young poor responder:comparison of the luteal estradiol/gonadotropin-releasing hormone antagonist priming protocol versus oral contraceptive microdose leuprolide.Fertil Steril,2011,95:592-595.
35 Bendikson K,Milki AA,Speck-Zulak A,et al.Comparison of GnRH antagonist cycles with and without oral contraceptive pretreatment in potential poor prognosis patients.Clin Exp Obstet Gynecol,2006,33:145-147.
36 Elassar A,Nulsen J,Engmann L,et al.Estradiol and antagonist pretreatment prior to microdose leuprolide in in vitro fertilization.Does it improve IVF outcomes in poor responders as compared to oral contraceptive pill.J Reprod Med,2015,60:199-204.
37 Kasapoglu T.;Polat M.;Boynukalin K,et al.Oral contraceptive (OCP) pretreatment is detrimental for pregnancy outcome in poor ovarian responders (PORs) undergoing IVF employing the letrozole/antagonist (L/A) protocol.Fertil Stetil,2013,100:S105.